Published in Blood on September 20, 2013
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol (2014) 3.94
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest (2016) 1.75
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood (2016) 1.72
Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (2014) 1.64
Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood (2015) 1.57
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood (2015) 1.53
Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer (2016) 1.51
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med (2014) 1.44
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol (2017) 1.39
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol (2016) 1.39
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia (2014) 1.13
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov (2015) 1.09
CD19-CAR trials. Cancer J (2014) 1.09
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A (2016) 1.09
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther (2014) 1.08
Toxicities of chimeric antigen receptor T cells: recognition and management. Blood (2016) 1.07
CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med (2015) 1.04
Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol (2015) 1.03
Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology (2014) 1.03
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med (2016) 1.01
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood (2015) 1.00
Are natural killer cells superior CAR drivers? Oncoimmunology (2014) 0.99
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther (2017) 0.96
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J (2014) 0.95
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front Immunol (2015) 0.94
Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol (2016) 0.93
New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell (2015) 0.93
Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics (2016) 0.93
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia (2013) 0.92
Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing. PLoS One (2014) 0.92
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology (2015) 0.92
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood (2016) 0.89
Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet (2015) 0.89
Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep (2014) 0.89
Driving gene-engineered T cell immunotherapy of cancer. Cell Res (2016) 0.89
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs (2015) 0.86
Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia (2014) 0.86
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood (2016) 0.86
CAR-T Cell Therapy for Lymphoma. Annu Rev Med (2015) 0.86
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest (2016) 0.85
The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer (2014) 0.85
Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget (2015) 0.85
Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy (2016) 0.85
Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev (2016) 0.85
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia (2014) 0.85
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med (2017) 0.84
Lymphoma Immunotherapy: Current Status. Front Immunol (2015) 0.84
Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia (2014) 0.82
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med (2016) 0.82
Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. Oncotarget (2016) 0.82
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. Am J Cancer Res (2016) 0.81
Blood's 70th anniversary: CARs on the Blood highway. Blood (2016) 0.81
Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant (2015) 0.81
A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control. Cancer Immunol Immunother (2014) 0.81
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol (2016) 0.81
Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol (2015) 0.81
New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant (2015) 0.80
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther (2017) 0.80
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? Immunotherapy (2015) 0.80
Progress and prospects for engineered T cell therapies. Br J Haematol (2014) 0.80
Current challenges and novel treatment strategies in double hit lymphomas. Ther Adv Hematol (2016) 0.80
Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Ultra-high Risk Features and Benchmarking for Experimental Therapies. Am J Hematol (2016) 0.79
Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol (2015) 0.79
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Mol Ther (2016) 0.78
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev (2017) 0.78
Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. Biol Blood Marrow Transplant (2015) 0.78
"No donor"? Consider a haploidentical transplant. Blood Rev (2014) 0.78
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk (2014) 0.77
Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity. J Immunol (2015) 0.77
Advances in T-cell therapy for ALL. Best Pract Res Clin Haematol (2014) 0.77
Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol (2015) 0.77
Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid. Am J Cancer Res (2016) 0.77
Therapeutic T cell engineering. Nature (2017) 0.77
Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells. Mol Ther Methods Clin Dev (2017) 0.76
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med (2015) 0.76
Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. Hum Gene Ther (2015) 0.76
Chimeric antigen receptor-modified T cells strike back. Int Immunol (2016) 0.76
An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer. Oncoimmunology (2013) 0.76
Gene-modified hematopoietic stem cells for cancer immunotherapy. Hum Vaccin Immunother (2014) 0.76
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol (2017) 0.76
Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study. Leukemia (2014) 0.76
Paving the road ahead for CD19 CAR T-cell therapy. Curr Opin Hematol (2015) 0.76
Genome-Edited T Cell Therapies. Curr Stem Cell Rep (2017) 0.76
Adoptive Immunotherapy for Leukemia with Ex Vivo Expanded T Cells. Curr Drug Targets (2015) 0.75
Donating used CARs. Blood (2013) 0.75
Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds. J Immunother Cancer (2016) 0.75
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Oncologist (2016) 0.75
Chimeric Antigen Receptor T Cell Therapy in Hematology. Turk J Haematol (2015) 0.75
Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation. Iran J Pharm Res (2016) 0.75
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA. Oncoimmunology (2016) 0.75
Immunotherapy in Tumors. Dtsch Arztebl Int (2015) 0.75
Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy. Immunotargets Ther (2015) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
T cell exhaustion. Nat Immunol (2011) 11.08
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 5.23
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant (2010) 3.79
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood (2002) 3.57
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood (2011) 2.68
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood (2010) 2.45
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Adoptive T cell therapy of cancer. Curr Opin Immunol (2010) 2.13
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
Graft-versus-leukemia reactions in allogeneic chimeras. Blood (2003) 1.84
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.72
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.56
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother (2012) 1.47
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol (2012) 1.36
Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant (2008) 1.30
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev (2010) 1.28
Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant (2009) 1.27
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol (2010) 1.25
Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther (2011) 1.24
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood (2012) 1.23
Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens (2013) 1.22
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med (1993) 1.20
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol (2008) 1.17
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One (2013) 1.14
Engineered T cells for anti-cancer therapy. Curr Opin Immunol (2012) 1.12
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood (2013) 0.99
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood (2012) 0.90
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood (2011) 4.21
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol (2005) 4.10
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2005) 4.06
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res (2006) 3.52
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther (2005) 3.49
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 3.48
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol (2005) 3.15
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol (2006) 3.15
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood (2004) 3.05
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood (2011) 3.02
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest (2007) 3.02
Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor. Oncogene (2002) 2.97
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 2.86
Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest (2005) 2.84
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol (2005) 2.83
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood (2013) 2.82
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A (2004) 2.70
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood (2011) 2.66
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63